BUY Morepen Laboratories Limited — Sumeet Bagadia, Choice Broking
bySumeet Bagadia, Choice BrokingHorizon: NA (inferred 1–3 months)16 Aug 2026via LiveMint Buy-or-Sell (topic)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Morepen Labs shares jump 9%, snap three-day losing streak; Here's what you need to know
NewsCnbc-Tv18·13 Aug · 5d ago
Morepen Labs Q1 Results: Stock hits 20% upper circuit as CDMO scale-up drives record earnings
NewsCnbc-Tv18·4 Aug · 2w ago
Morepen Laboratories achieved its highest-ever quarterly revenue and earnings in Q1 FY27, with EBITDA growing 207% and PAT by 394%. The CDMO business has entered full-scale commercialization.
NSE · Press Release·4 Aug · 2w ago
Morepen Laboratories reported highest-ever quarterly revenue and earnings in Q1'FY27. EBITDA grew by 207% and PAT by 394%. The company's CDMO mandate entered full-scale commercialization.
BSE · Company Update·4 Aug · 2w ago
Morepen RX Limited, a wholly-owned subsidiary, has allotted equity shares. The financial impact and details of the allotment are not specified.
BSE · Company Update·6 Aug · 2w ago
Morepen Laboratories Limited announced its un-audited financial results for the quarter ended June 30, 2026. The board also approved the record date for final dividend and extension for hiving off Med
NSE · Outcome of Board Meeting·4 Aug · 2w ago
Morepen Laboratories Ltd has attached the financial results for the first quarter of the financial year 2027.
BSE · Board Meeting·4 Aug · 2w ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.